Neil Shah, MD, PhD

University of California, Berkeley, BS,1984, Genetics
University of California, Los Angeles, PhD, 1992, Microbiology & Molecular Genetics
University of California, Los Angeles, MD, 1996, Medicine

• 1984-1987
  Staff Research Associate, University of California, Los Angeles (UCLA), laboratory of Irvin S.-Y. Chen
• 1987-1992
  Graduate Student Researcher, UCLA, laboratory of Owen N. Witte
• 1996-1998
  Internship and Residency, UCLA School of Medicine
• 1998-2000
  Clinical part of Fellowship in Hematology/Oncology, UCLA School of Medicine
• 2000-2003
  Postdoctoral Fellow, UCLA, laboratory of Charles L. Sawyers
• 2003-2004
  Clinical Instructor, Division of Hematology/Oncology, UCLA School of Medicine
• 2004-2006
  Visiting Assistant Professor, Division of Hematology/Oncology, UCLA School of Medicine
• 2006-present
  Assistant Professor, Division of Hematology/Oncology, University of California, San Francisco (UCSF) School of Medicine

• 1989-1991
  National Institutes of Health Predoctoral Award in Tumor Cell Biology
• 1995
  Alpha Omega Alpha Medical Student Research Prize
• 1995-2003
  UCLA Specialty Training and Advanced Research (STAR) Award
• 2001-2004
  Leukemia and Lymphoma Society Career Development Award for Fellows
• 2003-2005
  NIH K12 Award in Clinical Pharmacology
• 2004-2007
  Leukemia and Lymphoma Society Career Development Award for Special Fellows
• 2006-2009
  Doris Duke Charitable Foundation Clinical Scientist Development Award
• 2009-2014
  Leukemia and Lymphoma Society Scholar in Clinical Research Award

• Shah, NP, HM Kantarjian, D-W Kim, D Rea, PE Dorlhiac-Llacer, JH Milone, J Vela-Ojeda, RT Silver, HJ Khoury, A Charbonnier, N Khoroshko, RL Paquette, M Deininger, RH Collins, I Otera, T Hughes, E Bleickardt, L Strauss, S Francis and A Hochhaus. 2008. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic phase chronic myeloid leukemia. J Clin Onc 2008 26:3204-3212.
• Shah, NP, BJ Skaggs, S Branford, TP Hughes, JM Nicoll, RL Paquette and CL Sawyers. 2007. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 117:2562-2569.
• Kantarjian, H, R Pasquini, N Hamerschlak, P Rousselot, J Holowiecki, S Jootar, T Robak, N Khoroshko, T Masszi, A Skotnicki, A Hellmann, A Zaritsky, A Golenkov, J Radich, T Hughes, A Countouriotis and N Shah. 2007. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase-II trial. Blood 109:5143-5150.
• Hochhaus, A, HM Kantarjian, M Baccarini, JH Lipton, JF Apperley, BJ Druker, T Facon, SL Goldberg, F Cervantes, D Niederwieser, RT Silver, RM Stone, TP Hughes, MC Muller, R Ezzeddine, AM Countouriotis and NP Shah. 2007. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109:2303-2309.
• Shah, NP, FY Lee, R Luo, Y Jiang, M Donker and C Akin. 2006. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activation mutation that triggers neoplastic growth in the majority of patients with systemic mastocytosis. Blood 108:286-291.
• Talpaz, M, NP Shah, H Kantarjian, N Donato, J Nicoll, R Paquette, J Cortes, S O'Brien, C Nicaise, E Bleickardt, MA Blackwood-Chirchir, V Iyer, T-T Chen, F Huang, AP Decillis and CL Sawyers. 2006. Activity of the ABL Kinase Inhibitor Dasatinib in Imatinib-Resistant Philadelphia Chromosome Positive Leukemias. NEJM: 354:2531-2541.
• Young, MA, NP Shah, LH Chao, M Seeliger, ZV Milanov, WH Biggs, DK Treiber, HK Patel, PP Zarrinkar, DJ Lockhart, CL Sawyers and J Kuriyan. 2006. Structure of the kinase domain of imatinib-resistant ABL mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 66:1007-1014.
• Michor, F, TP Hughes, Y Iwasa, S Branford, NP Shah, CL Sawyers and MA Nowak. 2005. Dynamics of chronic myeloid leukemia. Nature 435:1267-1270.
• Burgess, MR, BJ Skaggs, NP Shah, FY Lee and CL Sawyers. 2005. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA:102:3395-3400.
• Shah, NP, C Tran, FY Lee, D Norris, P Chen and CL Sawyers. 2004. Overriding imatinib resistance with a novel ABL inhibitor. Science 305:399-401.
• Shah, NP, JM Nicoll, B Nagar, ME Gorre, RL Paquette, J Kuriyan and CL Sawyers. 2002. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-125.
• Roumiantsev, S, NP Shah, ME Gorre, JM Nicoll, BB Brasher, CL Sawyers and RA van Etten. 2002. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA 16:10700-10705.
• Shah, NP, ON Witte and CT Denny. 1991. Characterization of the BCR promoter in Philadelphia chromosome-positive and -negative cell lines. Mol Cell Biol 11:1854-1860.
• Denny, CT, NP Shah, S Ogden, C Willman, T McConnell, W Crist, A Carroll and ON Witte. 1989. Localization of preferential sites of rearrangement within the BCR gene in Philadelphia chromosome-positive acute lymphoblastic leukemia. Proc Natl Acad Sci USA 86:4254-4258.
• Rosenblatt JD, AJ Cann, DJ Slamon, IS Smalberg, NP Shah, J Fujii, W Wachsman and IS-Y Chen. 1988. HTLV-II trans-activation is regulated by two overlapping nonstructural genes. Science 240:916-919.
• Kitado, H, IS-Y Chen, NP Shah, AJ Cann, K Shimotohno and H Fan. 1987. U3 sequences from HTLV-I and -II LTRs confer px protein response to a murine leukemia virus LTR. Science 235:901-904.
• Wachsman, W, AJ Cann, JL Williams, DJ Slamon, L Souza, NP Shah and IS-Y Chen. 1987. HTLV x gene mutants exhibit novel transcriptional regulatory phenotypes. Science 235:674-677.
• Shah, NP, W Wachsman, L Souza, AJ Cann, DJ Slamon and IS-Y Chen. 1986. Comparison of the trans-activation properties of the HTLV-I and HTLV-II x proteins. Mol Cell Biol 6:3626-3631.
• Chen, IS-Y, AJ Cann, NP Shah and RB Gaynor. 1985. Functional relation between HTLV x and adenovirus EIA proteins in transcriptional activation. Science 230:570-573.
• Cann, AJ, JD Rosenblatt, W Wachsman, NP Shah and IS-Y Chen. 1985. Identification of the gene responsible for human T-cell leukemia virus transcription regulation. Nature (London) 318:571-574.
• Chen, IS-Y, DJ Slamon, JD Rosenblatt, NP Shah, SG Quan and W Wachsman. 1985. The x gene is essential for HTLV replication. Science 229:54-58.